These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
88 related articles for article (PubMed ID: 26181424)
1. Trametinib-induced Left Ventricular Dysfunction in a Child With Relapsed Neuroblastoma. Modak S; Asante-Korang A; Steinherz LJ; Grana N J Pediatr Hematol Oncol; 2015 Aug; 37(6):e381-3. PubMed ID: 26181424 [TBL] [Abstract][Full Text] [Related]
2. Cardiovascular Effects of the MEK Inhibitor, Trametinib: A Case Report, Literature Review, and Consideration of Mechanism. Banks M; Crowell K; Proctor A; Jensen BC Cardiovasc Toxicol; 2017 Oct; 17(4):487-493. PubMed ID: 28861837 [TBL] [Abstract][Full Text] [Related]
3. Valencia-Sama I; Ladumor Y; Kee L; Adderley T; Christopher G; Robinson CM; Kano Y; Ohh M; Irwin MS Cancer Res; 2020 Aug; 80(16):3413-3423. PubMed ID: 32586982 [TBL] [Abstract][Full Text] [Related]
4. The role of MEK inhibitors in the treatment of metastatic melanoma. Grimaldi AM; Simeone E; Ascierto PA Curr Opin Oncol; 2014 Mar; 26(2):196-203. PubMed ID: 24419498 [TBL] [Abstract][Full Text] [Related]
5. Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanoma. Menzies AM; Long GV Clin Cancer Res; 2014 Apr; 20(8):2035-43. PubMed ID: 24583796 [TBL] [Abstract][Full Text] [Related]
6. Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myeloma. Tolcher AW; Patnaik A; Papadopoulos KP; Rasco DW; Becerra CR; Allred AJ; Orford K; Aktan G; Ferron-Brady G; Ibrahim N; Gauvin J; Motwani M; Cornfeld M Cancer Chemother Pharmacol; 2015 Jan; 75(1):183-9. PubMed ID: 25417902 [TBL] [Abstract][Full Text] [Related]
7. Phase 1 study to evaluate the effect of the MEK inhibitor trametinib on cardiac repolarization in patients with solid tumours. Patnaik A; Tolcher A; Papadopoulos KP; Beeram M; Rasco D; Werner TL; Bauman JW; Scheuber A; Cox DS; Patel BR; Zhou Y; Hamid M; Schramek D; Sharma S Cancer Chemother Pharmacol; 2016 Sep; 78(3):491-500. PubMed ID: 27392790 [TBL] [Abstract][Full Text] [Related]
8. In vivo effects of short- and long-term MAPK pathway inhibition against neuroblastoma. Takeuchi Y; Tanaka T; Higashi M; Fumino S; Iehara T; Hosoi H; Sakai T; Tajiri T J Pediatr Surg; 2018 Dec; 53(12):2454-2459. PubMed ID: 30266481 [TBL] [Abstract][Full Text] [Related]
9. Functional and genetic screening of acute myeloid leukemia associated with mediastinal germ cell tumor identifies MEK inhibitor as an active clinical agent. Leonard JT; Raess PW; Dunlap J; Hayes-Lattin B; Tyner JW; Traer E J Hematol Oncol; 2016 Mar; 9():31. PubMed ID: 27036514 [TBL] [Abstract][Full Text] [Related]
10. Dropped-head syndrome in a patient under treatment with the MEK inhibitor trametinib for NRAS-mutated metastatic melanoma. Kleemann J; Hrgovic I; Hempel K; Kaufmann R; Meissner M Clin Exp Dermatol; 2018 Mar; 43(2):195-196. PubMed ID: 29023842 [No Abstract] [Full Text] [Related]
11. Ocular toxicity due to Trametinib and Dabrafenib. Sarny S; Neumayer M; Kofler J; El-Shabrawi Y BMC Ophthalmol; 2017 Aug; 17(1):146. PubMed ID: 28818062 [TBL] [Abstract][Full Text] [Related]
12. Anti-relapse effect of trametinib on a local minimal residual disease neuroblastoma mouse model. Togashi Y; Tanaka T; Takemoto M; Takeuchi Y; Higashi M; Fumino S; Tajiri T J Pediatr Surg; 2021 Jul; 56(7):1233-1239. PubMed ID: 33863557 [TBL] [Abstract][Full Text] [Related]
13. Cutaneous Reactions in Children Treated with the Mitogen-Activated Protein Kinase Extracellular Signal-Regulated Kinase Inhibitor Trametinib for Neural Tumors. Boull C; Hook K; Moertel C; Maguiness S Pediatr Dermatol; 2017 Jan; 34(1):90-94. PubMed ID: 27981612 [TBL] [Abstract][Full Text] [Related]
14. Trametinib-associated Hyponatremia in a Child With Low-grade Glioma is Not Seen Following Treatment With Alternative MEK Inhibitor. Lazow MA; Lawson SA; Salloum R; Hummel TR; Pillay Smiley N; DeWire-Schottmiller MD; Fouladi M; de Blank P J Pediatr Hematol Oncol; 2021 May; 43(4):e550-e553. PubMed ID: 32520842 [TBL] [Abstract][Full Text] [Related]
15. Relapsing pneumonitis due to two distinct inhibitors of the MAPK/ERK pathway: report of a case. Giraud V; Longvert C; Houlle-Crepin S; Danel C; Labrune S; Camus P; Saiag P; Chinet T BMC Cancer; 2015 Oct; 15():732. PubMed ID: 26481107 [TBL] [Abstract][Full Text] [Related]
16. Role of the MEK inhibitor trametinib in the treatment of metastatic melanoma. King JW; Nathan PD Future Oncol; 2014; 10(9):1559-70. PubMed ID: 25145427 [TBL] [Abstract][Full Text] [Related]
17. Trametinib (GSK1120212) in the treatment of melanoma. Salama AK; Kim KB Expert Opin Pharmacother; 2013 Apr; 14(5):619-27. PubMed ID: 23432625 [TBL] [Abstract][Full Text] [Related]
18. Trametinib for the treatment of recurrent/progressive pediatric low-grade glioma. Manoharan N; Choi J; Chordas C; Zimmerman MA; Scully J; Clymer J; Filbin M; Ullrich NJ; Bandopadhayay P; Chi SN; Yeo KK J Neurooncol; 2020 Sep; 149(2):253-262. PubMed ID: 32780261 [TBL] [Abstract][Full Text] [Related]
20. Trametinib for a BRAF G469A missense mutation in a neuroblastoma unveiled by liquid biopsy. Toutain G; Min V; Rome A; Andre N Pediatr Blood Cancer; 2022 Nov; 69(11):e29742. PubMed ID: 35652680 [No Abstract] [Full Text] [Related] [Next] [New Search]